CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET
演讲将于美国东部时间2023年6月20日星期二上午 10:30 举行
ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20, 2023, at 10:30 AM ET.
瑞士苏黎世/Accesswire/2023 年 6 月 19 日/ 专注于为罕见和复杂的中枢神经系统疾病患者发现和开发创新疗法的瑞士临床阶段生物制药公司NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP，NLSPW）（“NLS” 或 “公司”）今天宣布，NLS Pharmaceutics首席执行官亚历克斯·兹威尔将出席由Maxim Group and LLC主办的医疗保健虚拟会议第二部分由 M-Vest 主办 美国东部时间 2023 年 6 月 20 日星期二上午 10:30。
The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space. These include multiple therapeutic categories and emerging technologies, which presenting companies at this year's Maxim Healthcare Conference are focused on, and for many, that includes key data-driven events in 2023. Maxim Senior Analysts will host a wide range of biotechnology and medical device companies in a series of presentations and interactive discussions with CEOs and key management. Maxim will also be hosting several topical industry panels that promise to be timely and engaging.
科学和医学知识和专业知识的指数级增长继续推动医疗保健领域的机遇。其中包括多个治疗类别和新兴技术，在今年的Maxim Healthcare Conference大会上，参展公司重点关注这些类别和新兴技术，对许多公司来说，其中包括2023年以数据为导向的关键活动。Maxim高级分析师将与首席执行官和关键管理层进行一系列演讲和互动讨论，邀请众多生物技术和医疗设备公司参加。Maxim还将主持几场主题行业小组讨论会，这些小组讨论有望及时且引人入胜。
This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.
该会议将在M-Vest上直播。要参加，只需注册成为M-Vest会员即可。
Click here to reserve your seat.
点击此处预订座位。
About NLS Pharmaceutics Ltd.
关于 NLS 制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP）是一家处于开发阶段的全球生物制药公司，与世界一流的合作伙伴和国际公认的科学家合作，专注于为医疗需求未得到满足的罕见复杂中枢神经系统（CNS）疾病患者发现和开发创新疗法。NLS 总部位于瑞士，成立于 2015 年，由一支经验丰富的管理团队领导，在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
欲了解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
玛丽安·兰伯森（投资者和媒体）
NLS 制药有限公司
+1 239.682.8500
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
来源： NLS 制药股份有限公司